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Background: Vaginal lactic acid bacteria defend the host against pathogens through a combination of competitive
exclusion, competition for nutrients, production of antimicrobial substances and through the activation of the
immune system. A new human isolate named Lactobacillus crispatus L1 was characterized in this work, and a
preliminary evaluation of its probiotic potential is described together with a process to obtain a high productivity
of viable biomass.
Results: In a simulated digestion process 1.8⋅1010 cells∙ml−1 survived the gastric environment with 80% viability,
without being affected by small intestine juices. Experiments on six different C sources were performed to analyze
growth and organic acids production and, glucose, provided the best performances. A microfiltration strategy was
exploited to improve the cellular yield in 2 L-fermentation processes, reaching 27 g · l−1 of dry biomass. Moreover,
L. crispatus L1 demonstrated a greater stability to high concentrations of lactic acid, compared to other lactobacilli.
The specific L. crispatus L1 exopolysaccharide was purified from the fermentation broth and characterized by
NMR showing structural features and similarity to exopolysaccharides produced by pathogenic strains. Live
L. crispatus L1 cells strongly reduced adhesion of a yeast pathogenic strain, Candida albicans in particular, in
adherence assays. Interestingly a higher expression of the human defensin HBD-2 was also observed in vaginal
cells treated with the purified exopolysaccharide, indicating a possible correlation with C. albicans growth
inhibition.
Conclusions: The paper describes the evaluation of L. crispatus L1 as potential vaginal probiotic and the
fermentation processes to obtain high concentrations of viable cells.
Keywords: L. crispatus L1, High cell densities cultivation, Simulated digestionBackground
Lactobacilli have long been of interest to the dairy and
agriculture industries, in fact, they are defined as generally
regarded as safe (e.g. through regulatory agency), and
some have been found as ubiquitous members of the
mucosae of healthy subjects [1]. Some studies describe
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article, unless otherwise stated.or prevention of infections of the intestinal and genital
tracts with different extents of success [2,3]. It is quite
difficult to identify which properties of lactobacilli are
required to prevent and eventually treat diseases and to
determine the adequate dosage, duration, and methods of
delivery.
In respect to vaginal probiotics, the protective role of
lactobacilli seems to be based upon two mechanisms,
namely, the specific adherence to the vaginal epithe-
lium leading to intensive colonization of this surface,
and the control of the remaining vaginal microfloraentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the ability of lactobacillus to adhere to epithelial cells and
mucosal surfaces is a key criterion for the selection of
probiotics [4].
The efficacy of the available commercial products is also
strictly dependent on the viability of the probiotic strains
contained in the preparations, since the amount of applied
microorganism could be crucial for the effectiveness of
the product [5], and several studies revealed that some
health food products did not satisfy the claims stated on
the labels therefore minimizing the expected health
benefits [6]. Therefore the evaluation of cell viability in
conditions that mimic the practical application is a key
issue in the selection of probiotics.
Also the development of novel fermentation strategies
to increase the final biomass yield is central to bypass
one of the bottlenecks encountered in the production
of starters, probiotic ingredients and medical devices.
However, since their growth is inhibited by their pri-
mary metabolic product (pH lowering but also lactate
effect in buffered cultivations), lactobacilli are rarely
cultivated at high cellular density (i.e. higher than 8⋅109
cells∙ml−1) in batch/fed-batch fermentation processes.
Vaginal probiotics are a rather new area of investigation
and, therefore, not much is known about the mechanisms,
the conditions or characteristics needed to assess their
efficacy. Several strains appear to be effective in coloniz-
ing and then protecting the intestine and the urogenital
tract [7-9], from infections. Commercial lactobacilli-
based products such as Normogin® have demonstrated
to be a reliable treatment for reducing the recurrence of
bacterial vaginosis [10]. It has been reported that infec-
tion mechanisms are mainly due to a disestablishment
of the normal resident vaginal microflora, primarily a loss
of H2O2-producing lactobacilli [11,12], although some
studies do not support this hypothesis [13]. In vitro studies
have suggested that the re-colonization of the urinary tract
by certain specific strains of lactobacilli seems to be a
suitable approach to prevent infections and relapses
[14,15]. Recently it has also been suggested that some
probiotic bacteria could be effective not only when locally
delivered (e.g. vaginal instillation) but also when assumed
per os [16], and this establishes a link between the rate of
intestinal survival and vaginal colonization [17].
Lactobacillus crispatus can persist in the gastrointestinal
tract [18] and is among the most prevalent species of the
Lactobacillus-dominated human vaginal microbiota [19],
and resistance to very low pH conditions have also been
described [20].
A strain of L. crispatus (named L. crispatus L1) isolated
from the vaginal flora of a healthy woman was characte-
rized in this study. In particular, the ability of L. crispatus
L1 to survive to an in vitro simulated digestion was evalu-
ated and its physiological and metabolic requirementswere investigated. Optimal growth conditions were de-
fined, in order to obtain high density cultivations needed
for potential applications of this strain as probiotic supple-
ment. The use of an in situ product removal fermentation
process allowed a 7-fold improvement of the biomass
yield compared to traditional processes, accompanied by
an extremely high cellular viability (94%). Given the neces-
sity of probiotic preparations to deliver a certain amount
of viable microbial cells the effect of different protective
agents on freeze-drying procedures was also investigated.
Moreover, in order to investigate on the chemical nature
of the agents that are at the basis of the beneficial effect of
L. crispatus L1 we have established the primary structure of
its exopolysaccharides (EPS), since previous studies [21,22]
on bacterial adhesion showed that EPS might promote the
adherence of bacteria to biological surfaces, thereby facili-
tating the colonization of various ecological niches. Intri-
guingly, the EPS resulted to be a mannan polysaccharide
possessing a structure very similar to the one produced by
Candida albicans [23]. The EPS was found to be present
in adherent biofilms and might be involved in initial and
permanent adhesion. Moreover the EPS-induced increased
expression of the human defensin HBD-2 in vaginal cells
was also verified, identifying a possible connection with
C. albicans growth inhibition [24].
Results
Strain identification and H2O2 production
A Lactobacillus strain isolated from human vaginal secre-
tion was allotted to crispatus subspecies by 16S ribosomal
DNA sequencing [25] and it was named L. crispatus L1.
In particular, PCR products were pooled, purified and
sequenced.
In addition, the ability of 72 Lactobacillus strains to
produce H2O2 was evaluated. The percentage of strains
classified as strong, medium, weak and negative H2O2
producers was 23, 34, 38 and 5%, respectively. L. crispa-
tus L1 was found to be the best of the isolates in the la-
boratory collection.
In vitro digestion
Results from shake flask experiments simulating the pas-
sage through the gastrointestinal tract showed a good re-
sistance of L. crispatus L1 to the in vitro digestion process.
The bacterial dose significantly influenced results, as shown
in Figure 1a clearly indicating that 1.8⋅109 cells∙ml−1 corre-
sponds to the minimal required initial concentration of
cells necessary to survive gastric juices. Incubation in simu-
lated pancreatic juices (Figure 1b) with different Oxgall
concentrations (10 mg and 25 mg) did not affect viability,
whereas a slight increase of the cell number within 4 h
was observed. Moreover, treated cells reached a final bio-
mass yield comparable with that of the control cells (data
not shown).
Figure 1 Simulation of human digestion in shake flasks.
(a) Survival of L. crispatus L1 to gastric juices (pH 2.0, pepsine 3 g∙l−1).
Response of different doses of bacteria, high (1.8 · 109 cells∙ml−1) and
low (6.0 · 108 cells∙ml−1), to the treatment. (b) Survival of L. crispatus L1
to pancreatic juices (pH 4.0, pancreatine 2 g∙l−1, Oxgall in different
concentrations). Effect of two different concentrations of bile salts on
the viability of 1.0 · 109 cells∙ml−1.The asterisks indicate a statistically
significant difference between samples with P < 0.01.
Table 1 Growth of L. crispatus L1 in shake flasks on SDM med








The concentration of biomass and lactic acid were measured in the broth after 24 h
indicates g of lactic acid produced per g of substrate; μ8h indicates the specific gro
different experiments with standard deviations ≤ 5%.
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A semidefined medium containing soy peptone (10 g∙l−1)
and yeast extract (2.5 g∙l−1) was used to investigate the
amount of biomass and lactic acid produced using dif-
ferent carbon sources (Table 1). The final titer of bio-
mass produced in shake flasks was very similar in all the
media analysed. The production of lactic acid was quite
high ranging between 7.5 and 13.1 g∙l−1 (Table 1) and
resulting in relevant Yp/s ranging between 0.68 and
0.89 g∙g−1. The Yp/s on dextrins could not be calculated
due to the presence of high molecular weight carbohy-
drates (glucose residues >7) that were not degraded and
metabolized as evidenced by High Performance Anion
Exchange Chromatography with Pulsed Amperometric
Detection (HPAEC-PAD) analyses.Batch and microfiltration fermentation processes
Glucose and sucrose were selected as carbon sources for
the following batch experiments.
During these experiments L. crispatus L1 demonstrated
a similar growth rate and final concentration of cells. The
maximum titer of biomass on the two substrates was
slightly different, in particular, 3.9 ± 0.2 gcdw∙l
−1 were ob-
tained on glucose and 3.4 ± 0.1 gcdw∙l
−1 on sucrose
(Table 2). The final amount of lactic acid was also quite
similar, and it corresponded to 12 and 14 g∙l−1 on glucose
and sucrose, respectively. Product (lactate) inhibition was
also studied to better characterize the physiology of L. cris-
patus L1. Increasing amounts of sodium lactate added to
the SDM medium at a fixed pH lowered the initial specific
growth rate (1–3 h). In particular, μ appeared to be re-
duced by half with 45 g∙l−1 lactate (Figure 2). In order to
dilute lactic acid and overcome inhibition problems, a bio-
reactor with microfiltration modules was used to perform
in situ product removal experiments (Figure 3). A max-
imum of 27.1 gcdw∙l
−1 in 45 h of growth were produced
with a final concentration of 46 g∙l−1 of lactic acid. As it is
shown in Table 3, a 7-fold improvement of the final titer
of biomass was achieved by microfiltration experiments
compared to previous batch processes. Moreover the total
amount of lactic acid produced was equal to 148 g (ϕ =ium supplemented with different carbon sources
Lactic acid (g · l−1) Yx/s (g · g








of growth. Yx/s indicates g of dry biomass produced per g of substrate; Yp/s
wth rate in h−1 calculated in the first 8 h of growth. Values are an average of 3
Table 2 Yield of biomass and lactic acid obtained in batch experiments of L. crispatus L1 grown on SDM supplemented
with 20 g · l−1 glucose or sucrose as main carbon sources
Carbon source Cell dry weight (g · l−1) Lactic acid (g · l−1) μmax (h
−1)
Glucose 3.8 ± 0.3 11.5 ± 0.5 0.84
Sucrose 3.3 ± 0.2 13.6 ± 0.4 0.60
The medium contained soy peptone and yeast extract as nitrogen sources.
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−1 (Table 3). All results
presented are average of at least 3 experiments.
EPS production and purification
The EPSs content in the fermentation broth ranged be-
tween 200–400 mg⋅l−1 and the initial protein titre was
estimated up to 50 fold. Protease was used to eliminate
these major contaminants of the exopolysaccarides,
and the following tangential ultrafiltration (UF)/ dia-
filtration (DF) was performed to further purify the
product and to remove salt and other smaller contaminants.
During UF the flux decreased from 8.3 to 7.3 l∙m−2 h−1 and
it increased again to 13.5 l∙m−2 h−1 during the DF phase
that lasted until reaching a conductivity of 0.8mS/cm. The
supernatant was concentrated 9 fold compared to the ini-
tial volume.
The recovery yield after membrane purification was on
average 85% and the purified EPSs solution had a pro-
tein content that was inferior to 0.5% w/w.
Structure determination of mannan polymer
Compositional and methylation analyses showed the
presence of different derivatives of mannose, such as ter-
minal Manp, 2-substituted Manp, 3-substituted Manp,Figure 2 Lactate inhibition curve. The graph shows the specific
growth rate of L. crispatus L1 using increasing concentrations of
sodium lactate in the medium at pH 6.5.6-substituted Manp and 2,6-substituted Manp. On this
ground, it could be deemed the presence of a very intri-
cate polymer only based on a mannose monosaccharide,
in which other mannose branching residues were attached
to a mannan backbone. The polysaccharide underwent
Nuclear Magnetic Resonance (NMR) analysis and even
though the 1H- (Figure 4) and 13C-NMR spectra appeared
rather complex, it was clearly related to the mannan poly-
saccharides already described [26]. 2D NMR and degrad-
ation procedures confirmed the structure, a 6-substituted
mannan backbone with small branching chains (one to
three units) of Manp residues (Figure 4).
Inhibition of C. albicans adhesion to Vk2/E6E7
C. albicans is a constituent of the vaginal microbiota
and, as opportunistic pathogen, it causes genital infec-
tions in humans. In immuno-compromised individuals,
overgrowth of the fungus results in candidiasis. C. albicans
pathogenecity depends on several virulence traits that allow
the fungus to invade new tissues, evade the immune system
of the host, and facilitate the infection [27]. To verify the
antagonist effect of L. crispatus L1 against C. albicans,
the influence of the strain on the adhesion capacity of
C. albicans to immortalized human vaginal epithelial
cell line was evaluated.
The results demonstrate that there is a significantly re-
duced adhesion of C. albicans to Vk2/E6E7 cells by 58 ±Figure 3 Growth of L. crispatus L1 in a microfiltration
experiment. Time course of biomass, production of lactic acid and
residual glucose on SDM.
Table 3 Comparison of yields and productivities obtained in batch and microfiltration experiments of L. crispatus L1
Cell dry weight (g · l−1) Lactic acid (g · l−1) Biomass
productivity (g · l−1 · h−1)
Lactic acid
productivity (g · l−1 · h−1)
Yx/s (g · g
−1) Yp/s (g · g
−1)
Batch 3.8 ± 0.3 11.5 ± 0.5 0.20 ± 0.07 0.40 ± 0.02 0.20 ± 0.02 0.57 ± 0.03
MF 27.31 ± 1.5 46.02 ± 2.3 0.60 ± 0.03 0.70 ± 0.07 0.13 ± 0.08 0.75 ± 0.04
Yx/s indicates g of dry biomass produced per g of substrate; Yp/s indicates g of lactic acid produced per g of substrate. Values are an average of 3
different experiments.
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and displacement assays, respectively (Figure 5).
Moreover, confluent cell monolayers were treated with
increasing concentrations of EPS, isolated and purified
from L. crispatus L1, and successively infected with C.
albicans. The concentration required to interfere with
yeast adhesiveness was equal to 1.0 mg∙ml−1.
Figure 5b shows the effect of EPS on the adhesion of
C. albicans to vaginal epithelial cells under the condi-
tions of exclusion, competition and displacement. The
adhesion interference was of about 48% in the exclusion
assay, when the monolayers were pre-treated with
1.0 mg∙ml−1 EPS for 18 h and before addition of the C.
albicans suspension. In the competition and displace-
ment tests the reduction in adherence was comparable
to that obtained in the control experiment.
A set of experiments was performed to determine
whether HBD-2 was secreted by vaginal epithelial cells
treated with increasing concentrations of EPS. HBD-2
ELISAs showed that the concentration of HBD-2 protein
was significantly high in the supernatant after 18 h treat-
ment (Figure 6). Interestingly, the plateau was reached at
the same concentration (100 mg∙l−1).
Discussion
Lactobacilli are the prevailing bacteria of the vaginal flora
of healthy individuals that regulate the equilibrium be-
tween the resident microbiota and the vaginal environ-
ment [28]. Cervicovaginal microbiota not dominated by
lactobacilli may facilitate transmission of HIV and otherFigure 4 Characterization of the EPS produced by L. crispatus L1. 1H-N
mannan polysaccharide and structure of the EPS.sexually transmitted infections. L. crispatus, L. jensenii,
and to a lesser extent L. gasseri, are common in the vagina
of healthy women, whereas the dominance of L. iners is
associated with bacterial vaginosis [29]. Borgdorff and
colleagues [30] identified six microbiome clusters and
concluded that L. crispatus-dominated cervicovaginal
microbiota are associated with a lower prevalence of
sexually transmitted infections and a lower likelihood of
genital HIV-1 RNA shedding. Recent literature de-
scribes the identification of L. crispatus as a member of
the resident beneficial flora of the vaginal mucosae [31].
In agreement with this finding the strain isolated in this
work from vaginal fluids of a healthy woman was found
to belong to this species and named L. crispatus L1 .
Vaginal probiotics based on lactic acid bacteria have
been proposed as a valid strategy against recurrent infec-
tions. LAB use several mechanisms to create an un-
friendly environment for pathogens which include the
production of antimicrobial substances, such as organic
acids, hydrogen peroxide and bacteriocins, and the syn-
thesis of biofilms, in order colonize the vaginal mucosa
and displace the infective agents [7,31].
In view of a potential application of L. crispatus L1 as
vaginal probiotic, it was interesting to characterize the
properties of this new isolate due to the capacity of this
strain to modify the host microenvironment and there-
fore possibly deliver health benefits.
The production of lactic acid and hydrogen peroxide
were initially investigated and L. crispatus L1 demonstrated
the ability to produce both metabolites, and compared toMR spectrum and spin system attribution for each sugar of the
Figure 5 Inhibition of adhesion of C.albicans to vaginal
epithelial cells. (a) Treatment of vaginal epithelial cells with 1×107
L. crispatus. C. albicans to Vk2/E6E7 cells was assessed by microscopy
(×100) after Gram’s stain by counting the number of micro-organisms
attached to 30 consecutive cells. The results of the three conditions
(i.e. exclusion, competition and displacement) were expressed as the
average number of C. albicans per Vk2/E6E7 cells and compared with
adhesion without lactobacilli (control value). The control values were
taken as 100% of adhesion and the inhibition of C. albicans adherence
was calculated by subtracting each adhesion percentage from their
corresponding control value. (b) Treatment of vaginal epithelial cells
with 1.0 mg/mL EPS. C. albicans to Vk2/E6E7 cells was assessed by
microscopy (×100) after Gram’s stain by counting the number of
micro-organisms attached to 30 consecutive cells. The results of the
three conditions (i.e. exclusion, competition and displacement) were
expressed as the average number of C. albicans per Vk2/E6E7 cells and
compared with adhesion without EPS (control value). The control
values were taken as 100% of adhesion and the inhibition of C. albicans
adherence was calculated by substracting each adhesion percentage
from their corresponding control value. The data are expressed as
the mean ± SD percentage of adherence in three independent
experiments. The asterisks indicate a statistically significant difference
between C. albicans grown in the presence of viable or heat-killed
L. crispatus versus C. albicans alone. *P < 0.05, **P < 0.01.
Figure 6 HBD-2 levels in Vk2/E6E7cells after treatment with
EPS (0.01-0.1-1.0 - 5 mg/mL) secreted by L. crispatus L1. The
concentration of HBD-2 secreted in supernatant was measured
by ELISA.
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high concentrations of lactic acid, therefore enhancing
its competition capacity. Several studies assessed the
effectiveness of oral administration of vaginal probiotic
bacteria [16,17,33]. For this reason we monitored the re-
sistance of L. crispatus L1 to a simulated digestion process
by incubating the bacterium in shake flasks at pH 2 in the
presence of pepsine. Data showed that strain survival was
linked to the dose of treated bacteria, and, that with a
starting concentration of 1.8⋅109 cell∙ml−1 cell viability was
apparently not affected by small intestine juices. In vitro
assays simulating exposure to pancreatic juices were also
performed showing that, unexpectedly, L. crispatus L1
was unaffected by the treatment. These data demonstrate
the strain’s potential to be orally delivered.
The perspective to use this strain for biotechnological
purposes prompted further studies regarding the devel-
opment of a medium that could enhance strain growth
and be suitable for industrial applications. Experiments
were initially performed in shake flasks to identify the
most suitable carbon source for maximizing the yield of
biomass and lactic acid, and sucrose and glucose were
chosen for further small scale batch experiments. As
shown in Table 2 the growth rate of L. crispatus L1 was
not affected by the two different carbon sources; a
slightly lower Yp/s was obtained with glucose, neverthe-
less, the latter is often preferred for industrial processes
and therefore it was selected for the following fermenta-
tion experiments. In order to increase the production of
biomass and related product a high cell density fermen-
tation process exploiting a microfiltration strategy was
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the toxic threshold for L .crispatus L1 (estimated to be
45 g · l−1, Figure 3). The feeding strategy avoided the
waste of carbon source and determined a 7-fold and a
4-fold increase of the final titer of biomass and lactic acid,
respectively, compared to previous batch experiments
(Table 3). Based on earlier studies on L. bulgaricus [34] a
higher improvement of the final biomass concentration
was expected. Probably the adhesion of cells to membrane
capillaries lowered transmembrane fluxes thus reducing
the medium exchange rate. However, the concentration of
biomass reached was very high compared to that obtained
by cultivating other lactobacilli; moreover, biomass re-
sulted extremely viable (94%) at the end of the experi-
ments (data not shown), valuable result for the foreseen
application in medical devices/ food supplements.
Adhesion seems to be one of the key factors determin-
ing the colonization of the digestive ecosystem. Consis-
tently the surface characteristics of lactobacilli are
expected to contribute in several ways to their interactions
with the host gastrointestinal tract and the gut microbiota,
affecting their survival, adherence to the host tissue and in-
teractions with themselves and with other bacteria. Since
EPS can have important influences on these processes and
on the colonization of the host [35,36] we also have in-
vestigated the chemical nature of the EPS produced by
L. crispatus L1. This structure resulted to be a very intri-
cate comb-like mannan polysaccharide that has been
already isolated and identified as capsule/EPS/protein
bound-EPS in a number of microorganisms, among these
in the yeast C. albicans [37]. We therefore hypothesised
that the similarity of structure between the EPS of L.
crispatus L1 and the carbohydrate part of mannopro-
teins and protein bound-polysaccharides excreted by
C. albicans could be in part responsible for contrasting
C. albicans infections. For this reason the ability of L.
crispatus L1 live cells or of the purified EPS to hinder
growth of C. albicans was analysed by performing adhe-
sion assays with vaginal cells. In particular three mecha-
nisms were evaluated: (ì) exclusion by adhered lactobacilli
or EPS, (ii) competition for and (iii) displacement of ad-
herent yeast cells. Live L. crispatus cells demonstrated the
ability to strongly reduce the adherence of invading yeast
cells in all types of assays, the most powerful being the
competition modality in which adherence was decreases
by 58% compared to the control. The purified EPS only
inhibited yeast adhesiveness if pre-incubated with vaginal
cells before the addition of C. albicans, whereas it was not
efficient in competing or displacing yeast cells.
As is known, human defensins, short cysteine-rich cat-
ionic proteins, are key components of the innate immune
system. The inducible human beta-defensins are anti-
microbial peptides with a broad spectrum of antibacterial
and antifungal activity. Human beta-defensin 2 (HBD-2) isprimarily produced by epithelial cells. The peptide is
highly inducible due to various stimuli and has a broad
spectrum antimicrobial activity that is cidal for Candida.
It was interesting to observe that the pre-treatment of
vaginal epithelial cells with EPS induced a high expression
of the antimicrobial peptide HBD-2 against C. albicans.
The up-regulation of HBD-2 might represent a further
mechanism of host protection against Candida infections.
Overall these data indicate that this molecule is at least in
part responsible of the impairment of C. albicans adhesion
to vaginal cells, thus also demonstrating that it has a main
role in the beneficial effect of L. crispatus L1 as a natural,
probiotic, microbicide for vaginal health. In the light of
the information above it is not surprising that L. crispatus
L1 synthesizes a mannan polysaccharide that closely re-
sembles the carbohydrate part of mannoproteins and pro-
tein bound-polysaccharides excreted by C. albicans. In
our opinion, this is a an important step towards the com-
prehension of the molecular mechanisms at the basis of
the probiotic effect of L. crispatus ssp.
Conclusions
The present work describes the identification of a new hu-
man isolate named L. crispatus L1 and its characterization
in order to demonstrate that it meets some of the criteria
that identify probiotic strains, such as the ability to pro-
duce high titers of lactic acid and H2O2. In view of its
potential application as oral vaginal probiotic, simulated
digestion treatments were performed demonstrating its
suitability for oral administration.
Growth optimization was initially analysed in shake
flasks and following microfiltration experiments allowed
reaching high yields of extremely viable biomass, a key
prerequisite for probiotic preparations.
The characterization of the structure of the EPS pro-
duced by L. crispatus L1 showed a similarity with surface
molecules produced by C. albicans and the inhibition of
the adherence of this yeast to vaginal cells in the presence
of live L. crispatus L1 further suggested an important role
of this bacterium as a promoter of vaginal health.
These achievements underlie the potential of L. crispatus
L1 as orally administered vaginal probiotic, and hence the
strain results interesting for biotechnological applications
in medical devices and oral supplements.
Methods
Materials
Yeast nitrogen base without aminoacids, bacto casitone
peptone and soy peptone were purchased from Difco
(Becton Dickinson, Le Pont De Claix, France). De Man,
Rogosa and Sharpe Medium (MRS), medium M17, bac-
teriological agar and the AnaeroGen Compact atmosphere
generation system for solid state incubation on petri
dishes were from Oxoid (Basingstoke, England). All other
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the buffers were purchased from Sigma-Aldrich (Milan,
Italy). A kit containing acetic acid, lactic acid, citric acid,
butyrric acid, iso-butyrric acid, succinic acid, oxalic acid,
maleic acid was obtained by Supelco (Milan, Italy) for the
analytical quantification of organic acids.
Microorganism and media
Vaginal fluids collected from healthy women (after in-
formed consent) were plated onto lactobacilli selective
medium, namely MRS-agar (Oxoid) and incubated in
anaerobic conditions (Gas-Pak System; BBL, Becton
Dickinson Biosciences) for 48 h at 37°C.
Microorganisms were maintained in MRS-broth as sus-
pended culture (stabs) at −80°C using glycerol (20% w/v)
as cryoprotectant. These stabs were used to inoculate
pyrex bottles (250 ml) completely filled with culture media
to study cell growth and lactic acid production under
microaerofilic conditions over a period of 24–30 h at 37°C,
in a rotary shaker (HT Aquatron, Infors, Switzerland) at
160 rpm. Experiments were performed by adding different
carbon sources (20 g∙l−1) to the semi-defined medium,
SDM [38]: in particular fructose, sucrose, lactose, trehalose
and dextrins were used alternatively to analyze how micro-
bial growth and organic acids production were affected.
Shake flask experiments were also performed adding so-
dium lactate (0–60 g∙l−1) at increasing concentrations in the
SDM, to evaluate strain growth inhibition.
Identification methods
Single colonies were collected from MRS plates and charac-
terized with the API 50 CHL system (BioMérieux) accord-
ing to the manufacturer’s instructions. In order to correctly
identify the Lactobacillus at species level, 16S ribosomal
DNA (rDNA) was sequenced [39]. The sequences of the se-
lected Lactobacillus-specific primers LcrisF (AGCGAGCG
GAACTAACAGATTTAC) and LcrisR (AGCTGATCATG
CGATCTGCTT) confirmed the amplification of a 154-bp
fragment of 16S rRNA from the reference strain L. cris-
patus ATCC33820 [40]. Briefly genomic DNA was ex-
tracted from pure cultures using a QIAamp DNA mini
kit (Qiagen) according to the manufacturer’s instruc-
tions. 4 μl of DNA (≈40 ng), in 50 μl reaction mixtures
containing 1× Fast Start High Fidelity PCR system mix
(Roche), and 100nM (each) primer were amplified. PCR
was performed with the GeneAmp PCR System 9700
(Perkin Elmer, Wellesley, Mass.) with an initial denatur-
ation step of 95°C for 15 min, followed by 40 cycles of
95°C for 15 s and 62°C for 1 min.
Determination of H2O2 production
Since is reported that the lack of vaginal H2O2 produ-
cing lactobacilli is associated with bacterial vaginosis, the
Lactobacillus isolates were also characterised for theirproduction of H2O2. The capacity of L. crispatus L1 to
produce H2O2 was tested with a semiquantitative assay on
tetramethylbenzidine agar plates [15] using Brucella agar
(Difco) containing 0.001% (w/v) horseradish peroxidase
(Sigma), 0.023% (w/v) tetramethylbenzidine (Sigma) and
1% (w/v) starch. This medium was supplemented with
0.5 mg of bovine haemin (Sigma) and 0.1 mg of vitamin
K1 (Sigma) in 100 ml of final volume. Serial dilutions of
lactobacilli were inoculated in the medium and incu-
bated in anaerobic conditions at 37°C for 72 h. Plates
were then exposed to ambient air and H2O2-producing
colonies were revealed by the appearance of a blue
colour. According to the colour intensity, the strains were
classified as strong, medium, weak or negative (white
colonies) producers [41].
Gastrointestinal survival: simulated gastric and
pancreatic juices
Shake flask experiments were performed to evaluate the
capability of L. crispatus L1 to survive the gastrointes-
tinal tract. Simulated gastric and pancreatic juices were
prepared by slightly modifying the protocols reported by
Kos and colleagues [42]. Briefly, gastric juices were sim-
ulated with a solution of NaCl, 125 mM, KCl 7 mM,
NaHCO3, 45 mM and pepsine (Sigma Aldrich) 0.3% (w/v),
with a final pH equal to 2 obtained by HCl addition. Either
6.0∙108 cells · ml−1 (low dose, minimal starting density for
shake flasks experiments necessary to avoid the lag phase)
or 1.8·109 cells · ml−1 (high dose, typical amount delivered
in probiotic commercial products) were inoculated into the
medium and incubated 2–3 h in shaker at 37°C and
110 rpm to simulate physiological conditions. This step was
followed by centrifugation (15 min at 1200 × g) and re-
suspension of the cells in a solution containing pancreatine
(Sigma Aldrich) 0.1% (w/v), Oxgall bile (Sigma Aldrich)
0.15% (w/v) with a final pH equal to 4, to simulate pancre-
atic juices. The suspension was incubated for 3 h, after
which cells were centrifuged and re-suspended in fresh
MRS medium to evaluate bacterial growth. At the end
of each step cell viability was measured by plating ali-
quotes and counting colony forming units (cfu).
Fermenter experiments
The fermenter used was a Biostat CT, Braun Biotech Inter-
national (Melsungen, Germany), 2 l working volume,
equipped with a digital control unit and connected to a PC
for remote control via MFCS-win software. L. crispatus L1
was grown at T = 37°C, pH = 6.5. The stirring velocity was
initially set to 100–200 rpm and increased up to 300 rpm
during the experiment. The medium was sparged with ni-
trogen after sterilization prior to inoculation for at least
30 min. Experiments in batch mode were carried out using
the SDM medium, controlling the pH by automatic
addition of NH4OH (2.5 M).
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in batch mode, and switching after 8–10 h to fed-batch
and approximately 4 h later to MF mode. The duration
of each phase was set based on lactate formation, carbon
source consumption rate and their influence on growth
rates. Filtered exhaust medium was replaced with a fresh
salt solution with a level controller, to maintain a con-
stant fermentation volume. Microorganisms were there-
fore held in the vessel and fed with appropriate profiles
generally ranging from 1 to 5 g · l−1 · h−1. However, differ-
ently from previous data [34], the C/N ratio in the nutri-
ent solution was lowered from 1/4 to 1/16 during the
MF phase to further decrease the impact of raw mate-
rials on process costs.
A Biostat C Braun Biotech International (Melsungen,
Germany) bioreactor with a 15 l working volume was
used for the production of exopolysaccharides. Two re-
peated batch experiments were carried out using SDM
medium as previously described, in order to purify
higher amounts of EPS to allow extensive structural
characterization.
Analytical methods
Cell growth was followed during experiments by measur-
ing absorbance at 600 nm on a Beckman DU 640 Spectro-
photometer (Milan, Italy). Samples collected every hour
were spinned down in an ALC PK 131R centrifuge at
2000×g, and the wet weight was measured after centrifu-
gation and washing in saline solution (0.9% NaCl w/v).
The washed pellet was dried overnight (16–18 h) at 85°C
and a calibration curve relating the absorbance value to
the cell dry weight was generated. One gram per litre of
dry cell weight corresponded to 1.9 OD600. This correl-
ation was extrapolated on many different fermentation
experiments. Cell number was also measured by direct
counts at the optical microscope and plating for viability
determination (cfu). The supernatant (1 ml) was ultrafil-
tered on a centricon tube (10 KDa Mw cut–off, Milli-
pore) at 5000×g to prepare the samples for analytical
quantification. The concentration of glucose, or other
carbon sources, was measured through HPAEC-PAD ana-
lysis performed with a Dionex chromatographer (model
DX 500); the organic acids from the culture broth and the
permeate solutions were analysed by HPLC as previously
described [34]. A quick off-line determination was ob-
tained for glucose by using the Haemo-Glukotest 20–
800 stripes (Boehringer-Manheim, In vitro diagnosticum).
EPSs purification and quantification
EPSs were collected and isolated from fermentation su-
pernatants of L. crispatus L1. To quantify EPSs during
growth, opportunely diafiltered supernatants were assayed
using the anthrone/H2SO4 method [43], using a glucose
solution as standard. After harvesting (e.g. 24 h) removalof cells was obtained by centrifugation (2000 × g 30 min)
and the supernatants were recovered to purify EPSs.
The developed downstream procedure consisted in a
pre-treatment of the fermentation supernatant with 4U
per litre of protease (Aspergillus oryzae 3.2 U⋅mg−1,
Sigma) for 60 min at room temperature followed by
membrane-based UF and DF steps. The procedure was
carried on Uniflux-10, (GE Healthcare, USA) an auto-
mated tangential flow filtration pilot system also
equipped with a sensor level to perform fed-batch con-
centration or constant volume DF; temperature probe
on the retentate line; pressure sensors and flow meters
on feed, retentate and permeate lines; pH meter, con-
ductivity meter and UV (with λ = 280 nm) detector on
the permeate line. It is connected to a PC and a UNI-
CORN TM software, that allows to control, manage
and monitor the process and its parameters. The
supernatant was ultrafiltered on 5KDa membranes
with a filtering area of 0.1 m2 and diafiltered with 5
volumes of distilled water. After addition of 0.08 M
NaCl the recovered retentate was precipitated with 6
volumes of acetone and ethanol (1:1 v/v). The pre-
cipitate was dried, resuspended in sterile water and
treated with active charcoal to decolorization and puri-
fication from accidental endotoxin contamination. Fi-
nally the concentrated EPS solution was microfiltered
on 0.22 μm membranes and lyophilized. The powder
obtained was used for further characterization.General analytical and spectroscopic methods
Determination of sugars residues and of their absolute
configuration, GLC and GLC-MS were all carried out as
described. 1D 2D NMR experiments were carried out as
described [44,45].Culturing of Vk2/E6E7cells
Vk2/E6E7, immortalized human vaginal epithelial cell
line (American Type Culture Collection), were grown
in 75-cm2 flasks (Falcon, Becton Dickinson Biosciences,
Milan, Italy) at 37°C (5% CO2) in Keratinocyte-Serum Free
medium (GIBCO-BRL San Giuliano Milanese, Milan,
Italy) with 0.1 ng∙ml−1 human recombinant EGF,
0.05 mg∙ml−1 bovine pituitary extract, and additional
calcium to a final concentration of 0.4 mM. The
medium was changed every 2 days. Confluent mono-
layers (2.5 × 105 cells) were grown in six-well tissue
culture plates (Falcon, Becton Dickinson Biosciences,
Milan, Italy) in Dulbecco’s modified Eagle’s medium
and Ham’s F12 medium (D-MEM) (GIBCO-BRL San
Giuliano Milanese, Milan, Italy), antibiotic-free and
FCS-free, for 24 h, before starting experiments. One
million Vk2/E6E7 cells/well were used for the adhe-
sion assay.
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competition with C. albicans for adherence
Cell suspensions of L. crispatus L1 were grown in MRS
broth at 37°C in anaerobic conditions.
C. albicans was identified on the basis of growth cha-
racteristics, colony morphology, cellular appearance, and
carbohydrate assimilation patterns using commercially
available ATB ID 32 C test kit (bioMérieux, Marcy/Etoile,
France) at the Operative Unit of Microbiology, Second
University of Naples, Italy. Yeast cells were prepared by
inoculating four colonies isolated from Saburaud agar
(Oxoid, Milan, Italy) plates in 6 ml Brain Heart infusion
broth (BHI broth) (Oxoid, Milan, Italy), and incubating
the suspension at 30°C for 18 h under constant shaking.
These conditions yield cultures composed primarily of
blastospores at the late exponential growth phase.
Cultures of microorganisms were collected by centri-
fugation from the broth cultures, washed three times
and finally suspended in phosphate-buffered saline (PBS;
pH 7.1). The working dilution of the microorganism sus-
pensions was determined by performing sequential mea-
surements of optical densities of cultures at 600 nm and
quantification of viable microorganisms by colony counts.
For each strain, the correlation between the OD600 and cfu
was established. The microorganism cells suspended in
DMEM were used for the adhesion and interference assays.
Adherence of L. crispatus L1 to Vk2/E6E7 cells was
assayed by a method described previously with slight
modifications [46]. Preliminary experiments using 10:1,
100:1, and 1000:1 multiplicities of infection (MOI) were
conducted to determine the optimal bacterial-to-epithelial
cell ratio in our adhesion model. These pilot investigations
demonstrated a saturation of adhesion of L. crispatus L1
to Vk2/E6E7 cells at a MOI of 10:1. Therefore, for all sub-
sequent adhesion experiments described in this study a
MOI of 10:1 was utilized.
Interference experiments were performed with C.
albicans, a potential vaginal pathogen, that showed a
significant capacity to adhere to host cells. The procedures
described by Osset et al. [47] were used, with some modi-
fications. For exclusion tests, 1×107 lactobacilli and vaginal
epithelial cells were incubated together for 1 h at 37°C in
microaerophilic conditions; afterwards, C. albicans cells
were added, and incubation was further continued for 1 h.
During competition tests, 1×107 lactobacilli and 1×107
C. albicans were mixed and Vk2/E6E7 cell monolayers
then inoculated and incubated for 1 h at 37°C in micro-
aerophilic conditions. For displacement tests, 1×107 C.
albicans and epithelial cells were incubated together for
1 h at 37°C in microaerophilic conditions. Successively,
1×107 lactobacilli were added and incubation was pro-
longed for 1 h. Vk2/E6E7 cells were scored for the pres-
ence and number of bacteria and C. albicans attached,
and cell observation was performed as indicated above.For exopolysaccharide-interference experiments, Vk2/
E6E7 cell monolayers were treated with EPS as follows:
for competition tests, exopolysaccharide (0.01-0.1-
1.0 mg∙ml−1) and 1×107 C. albicans were mixed and,
successively, Vk2/E6E7 cell monolayers were inoculated
and incubated for 1 h at 37°C in microaerophilic condi-
tions. For exclusion tests, vaginal epithelial cells were
pre-treated with EPS (0.01-0.1-1.0 mg∙ml−1), before
addition of the C. albicans suspension for 1 h at 37°C in
microaerophilic conditions. At the concentrations used,
the EPS did not affect epithelial cell viability. In prelimin-
ary experiments monolayers were pre-treated with EPS
for 1, 4, 6 and 18 h at 37°C in microaerophilic conditions.
Microorganism adhesion to Vk2/E6E7 cells was assessed
by microscopy (×100) after Gram’s stain by counting the
number of micro-organisms attached to 30 consecutive
cells. The results of the three conditions (i.e. exclusion,
competition and displacement) were expressed as the
average number of C. albicans per Vk2/E6E7 cells and
compared with adhesion without lactobacilli or EPS (con-
trol value). The control values were taken as 100% of ad-
hesion and the inhibition of C. albicans adherence was
calculated by subtracting each adhesion percentage from
its corresponding control value.
Adhesion experiments were conducted three times with
at least three replicates per group. A difference in mean
values was deemed significant if the P values were <0.05
or highly significant if the P values were <0.01. The three
experimental groups were compared using a one-way ana-
lysis of variance. Post hoc group comparisons were con-
ducted using the Student-Newman-Keuls test.
HBD- 2 ELISA
Semi-confluent Vk2/E6E7 were grown in six-well tis-
sue culture plates and were treated with EPS (0.01-0.1-
1.0 -5.0 mg∙ml−1) for 18 h. Cell-free supernatants were
recovered by centrifugation and assayed to establish
the concentration of Human beta-defensin 2 (HBD-2)
by an enzyme-linked immunosorbent assay (Phoenix
Pharmaceuticals, Inc.).
The data were presented as means ± standard errors.
All pair wise comparisons were examined using unpaired
Student’s two-tailed t-test. Differences were considered
significant when P ≤ 0.05.
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